For instance, galectin-3 retention of glycosylated cytokines in the tumor ECM on the one hand, and T-cell dysfunction due to galectin-3 on the other hand, as suggested by a more activated T-cell phenotype observed after intratumoral injection of galectin antagonists. This evidence concerns the gene LGALS3 and neoplasm.